BENDAMUSTINE HYDROCHLORIDE injection

מדינה: ארצות הברית

שפה: אנגלית

מקור: NLM (National Library of Medicine)

מרכיב פעיל:

BENDAMUSTINE HYDROCHLORIDE (UNII: 981Y8SX18M) (BENDAMUSTINE - UNII:9266D9P3PQ)

זמין מ:

Baxter Healthcare Corporation

מסלול נתינה (של תרופות):

INTRAVENOUS

סוג מרשם:

PRESCRIPTION DRUG

סממני תרפויטית:

Bendamustine Hydrochloride Injection is indicated for the treatment of adult patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. Bendamustine Hydrochloride Injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine Hydrochloride Injection is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, alcohol, or monothioglycerol. [see Warnings and Precautions (5.4)] Risk Summary In animal reproduction studies, intraperitoneal administration of bendamustine to pregnant mice and rats during organogenesis at doses 0.6 to 1.8 times the maximum recommended human dose (MRHD) resulted in embryo-fetal and/or infant mortality, structural abnormalities, and alterations to growth (see Data ). There are no available data on bendamustine hydrochloride use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Bendamustine hydrochloride was intraperitoneally administered once to mice from 210 mg/m2 (approximately 1.8 times the MRHD) during organogenesis and caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory rib, and spinal deformities) and decreased fetal body weights. This dose did not appear to be maternally toxic and lower doses were not evaluated. Repeat intraperitoneal administration of bendamustine hydrochloride in mice on gestation days 7 to 11 resulted in an increase in resorptions from 75 mg/m2 (approximately 0.6 times the MRHD) and an increase in abnormalities from 112.5 mg/m2 (approximately 0.9 times the MRHD), similar to those seen after a single intraperitoneal administration. Bendamustine hydrochloride was intraperitoneally administered once to rats from 120 mg/m2 (approximately the MRHD) on gestation days 4, 7, 9, 11, or 13 and caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in external (effect on tail, head, and herniation of external organs [exomphalos]) and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats. Risk Summary There are no data on the presence of bendamustine hydrochloride or its metabolites in either human or animal milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with Bendamustine Hydrochloride Injection, and for 1 week after the last dose. Bendamustine Hydrochloride Injection can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)] . Pregnancy Testing Pregnancy testing is recommended for females of reproductive potential prior to initiation of treatment with Bendamustine Hydrochloride Injection. Contraception Females Advise female patients of reproductive potential to use effective contraception during treatment with Bendamustine Hydrochloride Injection and for 6 months after the last dose. Males Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with Bendamustine Hydrochloride Injection and for 3 months after the last dose [see Nonclinical Toxicology (13.1)] . Infertility Based on findings from clinical studies, Bendamustine Hydrochloride Injection may impair male fertility. Impaired spermatogenesis, azoospermia, and total germinal aplasia have been reported in male patients treated with alkylating agents, especially in combination with other drugs. In some instances, spermatogenesis may return in patients in remission, but this may occur only several years after intensive chemotherapy has been discontinued. Advise patients of the potential risk to their reproductive capacities. Based on findings from animal studies, Bendamustine Hydrochloride Injection may impair male fertility due to an increase in morphologically abnormal spermatozoa. The long-term effects of Bendamustine Hydrochloride Injection on male fertility, including the reversibility of adverse effects, have not been studied [see Nonclinical Toxicology (13.1)] . Safety and effectiveness in pediatric patients have not been established. Safety, pharmacokinetics and efficacy were assessed in a single open-label trial (NCT01088984) in patients aged 1 to 19 years with relapsed or refractory acute leukemia, including 27 patients with acute lymphocytic leukemia (ALL) and 16 patients with acute myeloid leukemia (AML). Bendamustine hydrochloride was administered as an intravenous infusion over 60 minutes on Days 1 and 2 of each 21-day cycle. There was no treatment response (CR+ CRp) in any patient. The safety profile in these patients was consistent with that seen in adults, and no new safety signals were identified. The pharmacokinetics of bendamustine in 43 patients, aged 1 to 19 years (median age of 10 years) were within range of values previously observed in adults given the same dose based on body surface area. No overall differences in safety were observed between patients ≥65 years of age and younger patients. Efficacy was lower in patients 65 and over with CLL receiving bendamustine hydrochloride based upon an overall response rate of 47% for patients 65 and over and 70% for younger patients. Progression free survival was also longer in younger patients with CLL receiving bendamustine (19 months vs. 12 months). No overall differences in efficacy in patients with non-Hodgkin Lymphoma were observed between geriatric patients and younger patients. Do not use Bendamustine Hydrochloride Injection in patients with creatinine clearance (CLcr) < 30 mL/min [see Clinical Pharmacology (12.3)] . Do not use Bendamustine Hydrochloride Injection in patients with AST or ALT 2.5-10 × upper limit of normal (ULN) and total bilirubin 1.5-3 × ULN, or total bilirubin > 3 × ULN [see Clinical Pharmacology (12.3)]

leaflet_short:

Safe Handling and Disposal Bendamustine Hydrochloride Injection is a hazardous drug. Follow applicable special handling and disposal procedures1 . Care should be exercised in the handling and preparation of solutions prepared from Bendamustine Hydrochloride Injection. The use of gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or other accidental spillage. If gloves come in contact with Bendamustine Hydrochloride Injection prior to dilution, remove gloves and follow disposal procedures1 . If a solution of Bendamustine Hydrochloride Injection contacts the skin, wash the skin immediately and thoroughly with soap and water. If Bendamustine Hydrochloride Injection contacts the mucous membranes, flush thoroughly with water. How Supplied Bendamustine Hydrochloride Injection is supplied in individual cartons of 6 mL clear multiple-dose vials containing 100 mg of bendamustine hydrochloride as a clear and colorless to yellow solution. NDC 10019-079-01, 100 mg/4 mL (25 mg/mL). Storage Store Bendamustine Hydrochloride Injection in refrigerator, 2° to 8°C (36° to 46°F). Retain vial in original carton until contents are used to protect from light.

מצב אישור:

New Drug Application

מאפייני מוצר

BENDAMUSTINE HYDROCHLORIDE- BENDAMUSTINE HYDROCHLORIDE INJECTION
BAXTER HEALTHCARE CORPORATION
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BENDAMUSTINE
HYDROCHLORIDE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
BENDAMUSTINE HYDROCHLORIDE INJECTION.
BENDAMUSTINE HYDROCHLORIDE INJECTION, FOR INTRAVENOUS USE.
INITIAL U.S. APPROVAL: 2008
INDICATIONS AND USAGE
Bendamustine Hydrochloride Injection is an alkylating drug indicated
for treatment of adult patients with:
•
•
DOSAGE AND ADMINISTRATION
For CLL:
•
For NHL:
•
DOSAGE FORMS AND STRENGTHS
Injection: 100 mg/4 mL (25 mg/mL) in a multiple-dose vial. (3)
CONTRAINDICATIONS
Bendamustine Hydrochloride Injection is contraindicated in patients
with a history of a hypersensitivity
reaction to bendamustine, polyethylene glycol 400, alcohol, or
monothioglycerol. Reactions to
bendamustine hydrochloride have included anaphylaxis and anaphylactoid
reactions. (4, 5.4)
WARNINGS AND PRECAUTIONS
•
•
•
•
•
•
•
•
•
•
ADVERSE REACTIONS
Chronic lymphocytic leukemia (CLL). Efficacy relative to first line
therapies other than chlorambucil
has not been established. (1.1)
Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during
or within six months of
treatment with rituximab or a rituximab-containing regimen. (1.2)
100 mg/m infused intravenously over 30 minutes on Days 1 and 2 of a
28-day cycle, up to 6 cycles.
(2.1)
2
120 mg/m infused intravenously over 60 minutes on Days 1 and 2 of a
21-day cycle, up to 8 cycles.
(2.2)
2
Myelosuppression: Delay or reduce dose, and restart treatment based on
ANC and platelet count
recovery. (5.1)
Infections: Monitor for fever and other signs of infection or
reactivation of infections and treat
promptly. (5.2)
Progressive Multifocal Leukoencephalopathy (PML): Monitor for new or
worsening neurological,
cognitive or behavioral signs or symptoms suggestive of PML. (5.3)
Anaphylaxis and Infusion Reactions: Severe anaphylacti